Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 1
1980 1
1981 2
1982 4
1983 6
1984 5
1985 13
1986 10
1987 10
1988 20
1989 16
1990 31
1991 24
1992 27
1993 34
1994 48
1995 59
1996 58
1997 69
1998 91
1999 99
2000 117
2001 122
2002 128
2003 151
2004 150
2005 192
2006 178
2007 211
2008 219
2009 242
2010 277
2011 264
2012 289
2013 297
2014 381
2015 409
2016 392
2017 405
2018 454
2019 521
2020 575
2021 638
2022 667
2023 760
2024 955
2025 1213
2026 144

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,840 results

Results by year

Citations

2 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Diagnosis and Management of Dementia: Review.
Arvanitakis Z, Shah RC, Bennett DA. Arvanitakis Z, et al. JAMA. 2019 Oct 22;322(16):1589-1599. doi: 10.1001/jama.2019.4782. JAMA. 2019. PMID: 31638686 Free PMC article. Review.
OBSERVATIONS: Dementia is an acquired loss of cognition in multiple cognitive domains sufficiently severe to affect social or occupational function. In the United States, Alzheimer disease, one cause of dementia, affects 5.8 million people. Dementia is commonly asso …
OBSERVATIONS: Dementia is an acquired loss of cognition in multiple cognitive domains sufficiently severe to affect social or occupational f …
Young-onset dementia diagnosis, management and care: a narrative review.
Loi SM, Cations M, Velakoulis D. Loi SM, et al. Med J Aust. 2023 Mar 6;218(4):182-189. doi: 10.5694/mja2.51849. Epub 2023 Feb 19. Med J Aust. 2023. PMID: 36807325 Free PMC article. Review.
These include primary dementias such as Alzheimer disease, frontotemporal and vascular dementias; genetic/familial dementias; metabolic disorders; and secondary dementias such as those that result from alcohol use disorder, traumatic brain injury, and …
These include primary dementias such as Alzheimer disease, frontotemporal and vascular dementias; genetic/familial dementias; …
A 2025 update on treatment strategies for the Alzheimer's disease spectrum.
Wu CK, Fuh JL. Wu CK, et al. J Chin Med Assoc. 2025 Jul 1;88(7):495-502. doi: 10.1097/JCMA.0000000000001252. Epub 2025 May 30. J Chin Med Assoc. 2025. PMID: 40442885 Free PMC article. Review.
Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder with a continuum of stages ranging from preclinical/asymptomatic phase to severe dementia. Over the past decades, significant advances in diagnostic biomarkers and disease …
Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder with a continuum of stages ranging fro …
Mild Cognitive Impairment: Diagnosis and Subtypes.
Bradfield NI. Bradfield NI. Clin EEG Neurosci. 2023 Jan;54(1):4-11. doi: 10.1177/15500594211042708. Epub 2021 Sep 22. Clin EEG Neurosci. 2023. PMID: 34549629
Various consensus groups have proposed criteria for MCI in Alzheimer's disease (AD), Parkinson's disease, dementia with Lewy bodies, and vascular cognitive impairment. ...The main utilities of MCI as a nosology are to understand the natural history of neurode …
Various consensus groups have proposed criteria for MCI in Alzheimer's disease (AD), Parkinson's disease, dementia with …
Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society.
Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, Finkel SI, Gwyther LP, Khachaturian ZS, Lebowitz BD, McRae TD, Morris JC, Oakley F, Schneider LS, Streim JE, Sunderland T, Teri LA, Tune LE. Small GW, et al. JAMA. 1997 Oct 22-29;278(16):1363-71. JAMA. 1997. PMID: 9343469 Review.
OBJECTIVE: A consensus conference on the diagnosis and treatment of Alzheimer disease (AD) and related disorders was organized by the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geri …
OBJECTIVE: A consensus conference on the diagnosis and treatment of Alzheimer disease (AD) and related …
Effect of aromatherapy on patients with Alzheimer's disease.
Jimbo D, Kimura Y, Taniguchi M, Inoue M, Urakami K. Jimbo D, et al. Psychogeriatrics. 2009 Dec;9(4):173-9. doi: 10.1111/j.1479-8301.2009.00299.x. Psychogeriatrics. 2009. PMID: 20377818 Free article. Clinical Trial.
In the present study, we examined the curative effects of aromatherapy in dementia in 28 elderly people, 17 of whom had Alzheimer's disease (AD). METHODS: After a control period of 28 days, aromatherapy was performed over the following 28 days, with a wash out perio …
In the present study, we examined the curative effects of aromatherapy in dementia in 28 elderly people, 17 of whom had Alzheimer's …
Brain volume change following anti-amyloid beta immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy.
Belder CRS, Boche D, Nicoll JAR, Jaunmuktane Z, Zetterberg H, Schott JM, Barkhof F, Fox NC. Belder CRS, et al. Lancet Neurol. 2024 Oct;23(10):1025-1034. doi: 10.1016/S1474-4422(24)00335-1. Lancet Neurol. 2024. PMID: 39304242 Review.
Progressive cerebral volume loss on MRI is a hallmark of Alzheimer's disease and has been widely used as an outcome measure in clinical trials, with the prediction that disease-modifying treatments would slow loss. However, in trials of anti-amyloid im …
Progressive cerebral volume loss on MRI is a hallmark of Alzheimer's disease and has been widely used as an outcome measure in …
Alzheimer's disease.
Blass JP. Blass JP. Dis Mon. 1985 Apr;31(4):1-69. doi: 10.1016/0011-5029(85)90025-2. Dis Mon. 1985. PMID: 3886334 Review.
Alzheimer's disease is a complex and fascinating entity, clinically and neurobiologically. ...The functional disability can be correlated with the site and extent of brain damage, but why these cells deteriorate and die is not known. Diagnosis depends on iden …
Alzheimer's disease is a complex and fascinating entity, clinically and neurobiologically. ...The functional disability can be …
Extravaganza of Nanobiotechnology in the Diagnosis and Treatment of Dementia Patients.
Bhattacharya S. Bhattacharya S. Curr Pharm Biotechnol. 2023;24(9):1108-1121. doi: 10.2174/1385272827666221027103050. Curr Pharm Biotechnol. 2023. PMID: 36305141 Review.
Alzheimer's disease is the most common form of dementia. A slew of small molecule inhibitors developed over several decades has targeted dementia and related diseases. ...Drug-loaded nanosized formulations, such as polymeric nanoparticles, solid lipid nano tr …
Alzheimer's disease is the most common form of dementia. A slew of small molecule inhibitors developed over several decades ha …
Effects of Physical Activity in Nursing Home Residents with Dementia: A Randomized Controlled Trial.
Henskens M, Nauta IM, van Eekeren MCA, Scherder EJA. Henskens M, et al. Dement Geriatr Cogn Disord. 2018;46(1-2):60-80. doi: 10.1159/000491818. Epub 2018 Aug 24. Dement Geriatr Cogn Disord. 2018. PMID: 30145595 Free PMC article. Clinical Trial.
BACKGROUND/AIMS: There is no consensus regarding the optimal nonpharmacological intervention to slow down dementia-related decline. We examined whether physical stimulation interventions were effective in reducing cognitive, physical, mood, and behavioral decline in nursin …
BACKGROUND/AIMS: There is no consensus regarding the optimal nonpharmacological intervention to slow down dementia-related decline. W …
9,840 results